Brazil’s Largest Hospital Chain Moves to Absorb Leading Lab Group in Market Shake-Up

Rede D’Or, Brazil’s largest private hospital operator, is taking steps to buy Grupo Fleury, the country’s leading medical testing and diagnostic network.

The talks, confirmed by both companies in July 2025, show how two of Brazil’s strongest health businesses want to join forces as competition and costs rise.

Rede D’Or runs 79 hospitals and manages over 13,000 beds, with sites across Brazil’s biggest cities. In 2024, Rede D’Or earned R$51.3 billion in revenue and R$3.93 billion in profit. Its hospitals ran at a healthy 77% capacity.

The company keeps adding new beds, with plans to grow capacity by almost half over the next three years. Rede D’Or’s finances remain stable despite carrying R$17.8 billion in debt, with a manageable debt-to-earnings ratio.

Fleury, with over 22,000 employees and 5,000 doctors, focuses on lab tests, imaging, and specialty medical exams. It earned R$8.3 billion in revenue and R$616 million in profit last year.

Fleury keeps buying smaller labs but says it only expands when prices and culture fit its standards. This possible deal comes as Brazil’s private health market faces major changes.

No single group dominates, because rules and high costs keep the sector chopped up. Brazil’s aging population and new, expensive treatments push up bills for patients and insurers.

Big companies like Rede D’Or and Fleury see merging as the best way to save money, offer more to patients, and stand stronger against rising costs. The game has been building for years.

Fifteen years ago, Rede D’Or’s owners sold their lab chain to Fleury for about R$1.2 billion. Now, both sides see a chance to put hospital and testing services together under one roof.

If Rede D’Or succeeds, the joined company would handle everything from hospital stays to blood tests for millions of Brazilians. That could mean faster, better service for patients—if the two firms manage the change well.

For smaller rivals, though, it makes survival even harder in a market where size and reach matter more every year. This deal marks a big moment for Brazil’s health system, highlighting how the race for scale and efficiency is changing care as much as policy or medicine does.